NR4A1 and inflammatory breast carcinoma: Statistical analysis revealed that there are no significant differences in age, tumor size, tumor grade, status of lymph node metastasis, hormonal receptors, and receiving neoadjuvant chemotherapy between HCMV- and HCMV+ IBC patients.